Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

123 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Natural innate and adaptive immunity to cancer.
Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Vesely MD, et al. Among authors: kershaw mh. Annu Rev Immunol. 2011;29:235-71. doi: 10.1146/annurev-immunol-031210-101324. Annu Rev Immunol. 2011. PMID: 21219185 Review.
Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway.
Westwood JA, Kelly JM, Tanner JE, Kershaw MH, Smyth MJ, Hayakawa Y. Westwood JA, et al. Among authors: kershaw mh. J Immunol. 2004 Jan 15;172(2):757-61. doi: 10.4049/jimmunol.172.2.757. J Immunol. 2004. PMID: 14707044
Discovery of an innate cancer resistance gene?
Smyth MJ, Kershaw MH. Smyth MJ, et al. Among authors: kershaw mh. Mol Interv. 2003 Jun;3(4):186-9. doi: 10.1124/mi.3.4.186. Mol Interv. 2003. PMID: 14993445 No abstract available.
Cytokines in cancer immunity and immunotherapy.
Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Smyth MJ, et al. Among authors: kershaw mh. Immunol Rev. 2004 Dec;202:275-93. doi: 10.1111/j.0105-2896.2004.00199.x. Immunol Rev. 2004. PMID: 15546400 Review.
Gene modification strategies to induce tumor immunity.
Murphy A, Westwood JA, Teng MW, Moeller M, Darcy PK, Kershaw MH. Murphy A, et al. Among authors: kershaw mh. Immunity. 2005 Apr;22(4):403-14. doi: 10.1016/j.immuni.2005.03.007. Immunity. 2005. PMID: 15845446 Review.
Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer.
Williams BB, Wall M, Miao RY, Williams B, Bertoncello I, Kershaw MH, Mantamadiotis T, Haber M, Norris MD, Gautam A, Darcy PK, Ramsay RG. Williams BB, et al. Among authors: kershaw mh. Cancer Immunol Immunother. 2008 Nov;57(11):1635-45. doi: 10.1007/s00262-008-0497-2. Epub 2008 Apr 3. Cancer Immunol Immunother. 2008. PMID: 18386000
Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo.
Pegram HJ, Jackson JT, Smyth MJ, Kershaw MH, Darcy PK. Pegram HJ, et al. Among authors: kershaw mh. J Immunol. 2008 Sep 1;181(5):3449-55. doi: 10.4049/jimmunol.181.5.3449. J Immunol. 2008. PMID: 18714017
Characterizing the anti-tumor function of adoptively transferred NK cells in vivo.
Pegram HJ, Haynes NM, Smyth MJ, Kershaw MH, Darcy PK. Pegram HJ, et al. Among authors: kershaw mh. Cancer Immunol Immunother. 2010 Aug;59(8):1235-46. doi: 10.1007/s00262-010-0848-7. Epub 2010 Apr 8. Cancer Immunol Immunother. 2010. PMID: 20376439
Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.
Westwood JA, Darcy PK, Guru PM, Sharkey J, Pegram HJ, Amos SM, Smyth MJ, Kershaw MH. Westwood JA, et al. Among authors: kershaw mh. J Transl Med. 2010 Apr 28;8:42. doi: 10.1186/1479-5876-8-42. J Transl Med. 2010. PMID: 20426873 Free PMC article.
CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.
Haynes NM, Hawkins ED, Li M, McLaughlin NM, Hämmerling GJ, Schwendener R, Winoto A, Wensky A, Yagita H, Takeda K, Kershaw MH, Darcy PK, Smyth MJ. Haynes NM, et al. Among authors: kershaw mh. J Immunol. 2010 Jul 1;185(1):532-41. doi: 10.4049/jimmunol.0903624. Epub 2010 May 26. J Immunol. 2010. PMID: 20505139
123 results
Jump to page
Feedback